Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carmustine + cisplatin + cyclophosphamide + dexamethasone + etoposide + melphalan + paclitaxel
- Development stage
- Unknown
- Lead developer
- University of Maryland, Baltimore
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination regimen is a high-dose chemotherapy protocol followed by autologous peripheral blood stem cell transplantation (ASCT) and consolidation therapy. Investigated by the University of Maryland, Baltimore, the protocol was designed for patients with poor-prognosis low-grade non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). The treatment sequence involves an intensive conditioning phase using carmustine (BCNU) and melphalan to achieve bone marrow ablation, followed by stem cell support. This is followed by a consolidation phase consisting of the DCEP regimen (dexamethasone, cyclophosphamide, etoposide, and cisplatin) supplemented with paclitaxel and additional cisplatin. Paclitaxel, a taxane, acts by stabilizing microtubules and inhibiting cell division, while the other components provide synergistic DNA-damaging and pro-apoptotic effects to eradicate residual malignant cells and improve long-term outcomes in high-risk patients.
- Brand names
- TaxolPlatinolDecadronCytoxanEtopophosBiCNUAlkeran
- Other names
- DCEP + paclitaxel + cisplatinBCNU + melphalan + DCEP + Taxol + cisplatinHigh Dose BCNU/Melphalan + Stem Cell Transplant + DCEP/Taxol/Cisplatin
02
Targets
TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on carmustine + cisplatin + cyclophosphamide + dexamethasone + etoposide + melphalan + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carmustine + cisplatin + cyclophosphamide + dexamethasone + etoposide + melphalan + paclitaxel.